REVENUE (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in millions	2023		2022		2023		2022
Net product sales	$	10,917	$	11,485	$	21,965	$	22,793
Alliance revenues	179		199		323		387
Other revenues	130		203		275		355
Total Revenues	$	11,226	$	11,887	$	22,563	$	23,535

Revenue Recognition Gross-To-Net Adjustments

The following table summarizes GTN adjustments:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in millions	2023		2022		2023		2022
Gross product sales	$	18,111	$	17,299	$	35,399	$	33,949
GTN adjustments (a)
Charge-backs and cash discounts	(2,279)		(1,750)		(4,370)		(3,513)
Medicaid and Medicare rebates	(3,143)		(2,624)		(5,625)		(4,708)
Other rebates, returns, discounts and adjustments	(1,772)		(1,440)		(3,439)		(2,935)
Total GTN adjustments	(7,194)		(5,814)		(13,434)		(11,156)
Net product sales	$	10,917	$	11,485	$	21,965	$	22,793

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $11 million and $98 million for the three and six months ended June 30, 2023 and $123 million and $197 million for the three and six months ended June 30, 2022, respectively.

Revenue from External Customers by Products and Services

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in millions	2023		2022		2023		2022
In-Line Products
Eliquis	$	3,204	$	3,235	6,627		6,446
Opdivo	2,145		2,063		4,347		3,986
Pomalyst/Imnovid	847		908		1,679		1,734
Orencia	927		876		1,691		1,668
Sprycel	458		544		887		1,027
Yervoy	585		525		1,093		1,040
Mature and other products	472		512		939		1,049
Total In-Line Products	8,638		8,663		17,263		16,950
New Product Portfolio
Reblozyl	234		172		440		328
Abecma	132		89		279		156
Opdualag	154		58		271		64
Zeposia	100		66		178		102
Breyanzi	100		39		171		83
Onureg	44		32		78		55
Inrebic	27		23		52		41
Camzyos	46		3		75		3
Sotyktu	25		—		41		—
Total New Product Portfolio	862		482		1,585		832
Total In-Line Products and New Product Portfolio	9,500		9,145		18,848		17,782
Recent LOE Products(a)
Revlimid	1,468		2,501		3,218		5,298
Abraxane	258		241		497		455
Total Recent LOE Products	1,726		2,742		3,715		5,753
Total revenues	$	11,226	$	11,887	$	22,563	$	23,535
United States	$	7,891	$	8,268	$	15,924	$	15,962
International	3,160		3,427		6,309		7,154
Other(b)	175		192		330		419
Total revenues	$	11,226	$	11,887	$	22,563	$	23,535

(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.